Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-02 (smartkarma.com)
Strategic Reviews, Company Sales, and Litigation: Analyzing Active Portfolio Ideas - Special Situation Investments
Lifeway Foods is likely to be sold to Danone, with a potential 14%+ upside, following board changes. Sage Therapeutics rejected Biogen's offer...
Read more
2025-05-01 (law360.com)
Shareholders Claim Biogen Skipped $50M Drug Payment - UK
Former shareholders of a U.K.-based drug company accused Biogen of failing to make a $50 million payment under a deal to acquire the company and its nerve pain medication, on the first day of trial on Thursday.
Read more
2025-04-16 (usaherald.com)
Biogen, Genentech Set for June Trial Over MS Drug Royalties - USA Herald
Biogen Inc. and Genentech Inc. are heading to trial in June over a significant contract dispute concerning patent royalties on multiple sclerosis (MS) drug sales. A federal judge in California recently denied Biogen's motion for summary judgment, signaling that the case will proceed to trial. The lawsuit, originally filed by Genentech in February 2023, centers
Read more
2025-03-31 (jdsupra.com)
Securities Litigation Against Life Sciences Companies 2024 Year in Review | Goodwin - JDSupra
Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical,...
Read more
2025-03-31 (pharmaphorum.com)
Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla |
The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.
Read more
2025-03-28 (bloomberglaw.com)
Biogen Must Face Investors' Claim on Alzheimer's Drug Trial Data
Biogen Inc. investors can advance their claim that the company misrepresented clinical trial data for its Alzheimer's drug, a federal judge ruled.
Read more
2025-03-25 (law360.com)
Roche Voids Biogen's Protein Production Patent At EPO -
The European Patent Office has stripped Biogen of its protein production patent amid Roche's protests, ruling in a decision released Tuesday that the tech lacks novelty in light of a key ruling from the agency's top appeals panel.
Read more
2025-01-28 (juve-patent.com)
Generics companies successfully challenge Biogen's Dutch Tecfidera patent -
The District Court The Hague nullifed the Dutch part of Biogen's Tecfidera patent in a dispute with generics Mylan, Neuraxpharm and Sandoz.
Read more
2023-10-09 (marketscreener.com)
Chugai Pharmaceutical Files Patent Infringement Lawsuit Against Biogen, Bio-Thera |
Chugai Pharmaceutical , its parent company Roche and its subsidiary Genentech, has filed a patent infringement lawsuit in the United States District Court for the District of Massachusetts. In a...
Read more
2023-03-21 (biopharma-reporter.com)
Novartis and Biogen exit deals with Sangamo
Both Novartis and Biogen have terminated partnerships with Sangamo Therapeutics in the past week.
Read more
2022-11-10 (tmcnet.com)
Biogen Names Christopher Viehbacher President and Chief Executive Officer
Biogen Names Christopher Viehbacher President and Chief Executive Officer
Read more
2019-02-07 (barrons.com)
Biogen Stock Slips on a Setback in a Patent Dispute With Mylan
Mylan filled an inter partes review for Biogen's “514 patent,” the drug maker’s treatment patent on Tecfidera. The IPR was instituted on Wednesday, but the case likely won’t reach a conclusion until 2020.
Read more